You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • SAT0261 Which Conventional DMARD to Select in the Treatment of Psoriatic Arthritis (PSA)? Data From Nor-Dmard on 1351 Treatment Courses with Methotrexate (MTX), Sulfasalazine (SSZ) And Leflunomide (LEF)

Article info

Article menu
Download PDFPDF
Scientific Abstracts
Psoriatic arthritis
SAT0261 Which Conventional DMARD to Select in the Treatment of Psoriatic Arthritis (PSA)? Data From Nor-Dmard on 1351 Treatment Courses with Methotrexate (MTX), Sulfasalazine (SSZ) And Leflunomide (LEF)

Authors

Citation

Lie E, Fagerli KM, Rødevand E, et al
SAT0261 Which Conventional DMARD to Select in the Treatment of Psoriatic Arthritis (PSA)? Data From Nor-Dmard on 1351 Treatment Courses with Methotrexate (MTX), Sulfasalazine (SSZ) And Leflunomide (LEF)
Annals of the Rheumatic Diseases 2013;72:A670-A671.

Publication history

  • First published January 23, 2014.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions